Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.80M | 26.93M | 25.87M | 24.56M | 23.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.66M | 112.27M | 114.24M | 110.26M | 104.55M |
| Operating Income | -119.66M | -112.27M | -114.24M | -110.26M | -104.55M |
| Income Before Tax | -103.69M | -97.21M | -100.22M | -94.60M | -88.79M |
| Income Tax Expenses | -- | 0.00 | 0.00 | 232.00K | 232.00K |
| Earnings from Continuing Operations | -103.69 | -97.21 | -100.22 | -94.83 | -89.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.69M | -97.21M | -100.22M | -94.83M | -89.02M |
| EBIT | -119.66M | -112.27M | -114.24M | -110.26M | -104.55M |
| EBITDA | -119.40M | -111.97M | -113.93M | -109.95M | -104.24M |
| EPS Basic | -1.86 | -1.85 | -2.00 | -1.93 | -1.90 |
| Normalized Basic EPS | -1.16 | -1.15 | -1.25 | -1.21 | -1.20 |
| EPS Diluted | -1.86 | -1.85 | -2.00 | -1.93 | -1.90 |
| Normalized Diluted EPS | -1.16 | -1.15 | -1.25 | -1.21 | -1.20 |
| Average Basic Shares Outstanding | 226.46M | 214.11M | 200.28M | 196.25M | 188.25M |
| Average Diluted Shares Outstanding | 226.46M | 214.11M | 200.28M | 196.25M | 188.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |